Skip to search formSkip to main contentSkip to account menu

AMG 330

Known as: Bispecific T-cell Engager Antibody AMG 330, AMG330, Anti-CD33/CD3 BiTE Antibody AMG 330 
A proprietary recombinant bispecific T-cell engager (BiTE) antibody composed of two single-chain variable fragments (scFv), one directed against the… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
Antibody-based immunotherapy represents a promising strategy to target and eliminate chemoresistant leukemic cells in acute… 
2013
2013
Antibody-based immunotherapy represents a promising strategy to specifically target and eliminate chemoresistant leukemic cells… 
2009
2009
ZusammenfassungDie Verordnung (EG) Nr. 1394/2007 hat für die Arzneimittel für neuartige Therapien (Gentherapeutika, somatische… 
2009
2009
ZusammenfassungAuf dem Gebiet der Hämatologie wurde in den vergangenen 25 Jahren eine besonders effektive Studieninfrastruktur… 
1998
1998
Carbachol-stimulated insulin release in the RINm5F cell is associated with elevation of the cytosolic Ca2+ concentration ([Ca2+]i… 
1993
1993
We and others have previously shown that 12-O-tetracanoylphorbol-13-acetate (TPA), a protein kinase-C (PKC) activator, inhibits… 
1987
1987
In our search for the mechanisms by which the drug 1-O-alkyl-2-O-methylglycero-3-phosphocholine (AMG-PC) inhibits tumor growth…